Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: Beneficial effects of iloprost

Summary

Platelets critically contribute to atherothrombosis and worsening ischaemia in patients with peripheral arterial disease (PAD), eventually leading to critical limb ischaemia (CLI). Furthermore, persistent platelet activation despite antiplatelet therapy has been reported in this setting. The prostacyclin analogue iloprost is currently recommended in CLI patients for its effects in relieving symptoms by promoting local perfusion. In this study, we investigated the effects of iloprost infusion on urinary 11-dehydro-TXB2 and 8-iso-PGF2α excretion rate, as in vivoindexes of thromboxane-dependent platelet activation and lipid peroxidation, respectively, and on platelet-derived proinflammatory sCD40L and nitric oxide bioavailability in 44 patients with CLI while on chronic treatment with low-dose aspirin. Daily iloprost infusion for one-week significantly decreased urinary 11-dehydro-TXB2 [499 (277 – 807) vs. 380 (189 – 560) pg/mg creatinine, p < 0.0001] and 8-iso-PGF2α [533 (316 – 842) vs. 334 (196 – 540) pg/mg creatinine, p < 0.0001] as well as plasma sCD40L [1540 (1005 – 3015) vs. 948 (845 – 2030) pg/ml, p < 0.0001]. Furthermore, a significant increase in plasma nitrate plus nitrite levels has been observed [26.8 (18.8 – 35.9) vs. 43.7 (33.0 – 75.5) μM, p < 0.0001]. A significant direct correlation was also found between urinary 8-iso-PGF2α and 11-dehydro-TXB2 before and after iloprost treatment (Rho = 0.695, p < 0.0001). In conclusion, we report that a short-term course of iloprost is able to significantly reduce residual thromboxane biosynthesis, oxidative stress, endothelial dysfunction and platelet-derived inflammation in low-dose aspirin treated patients with CLI.

Keywords

Platelet - inflammation - iloprost - oxidative stress - endothelial dysfunction - critical limb ischaemia

^* Drs. Lessiani and Vazzana contributed equally to this work.

• References

• 1 Diehm C, Schuster A, Allenberg JR. et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105.
• 2 White C. Intermittent claudication. N Engl J Med 2007; 356: 1241-1250.
• 3 Hirsch AT, Haskal ZJ, Hertzer NR. et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-654.
• 4 Norgren L, Hiatt WR, Dormandy JA. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33: S1-75.
• 5 Berger JS, Krantz MJ, Kittelson JM. et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. J Am Med Assoc 2009; 301: 1909-1919.
• 6 CAPRIE Steering Committee.. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
• 7 Bhatt DL, Fox KA, Hacke W. et al. CHARISMA Investigators.. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
• 8 Anand S, Yusuf S, Xie C. et al. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227.
• 9 Yamada T, Ohta T, Ishibashi H. et al. Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs--comparison with other noninvasive diagnostic methods. J Vasc Surg 2008; 47: 318-323.
• 10 Sartori M, Favaretto E, Legnani C. et al. Thrombophilic risk factors and peripheral arterial disease severity. Thromb Haemost 2010; 104: 71-77.
• 11 Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 2010; 103: 696-709.
• 12 Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg 2010; 51: 230-241.
• 13 Matoba S, Matsubara H. Therapeutic angiogenesis for peripheral artery diseases by autologous bone marrow cell transplantation. Curr Pharm Des 2009; 15: 2769-2777.
• 14 Meini S, De Franco V, Auteri A. et al. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV). Int Angiol 2005; 24: 64-69.
• 15 Melillo E, Nuti M, Pedrinelli R. et al. Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia?. Minerva Cardioangiol 2006; 54: 481-498.
• 16 Critical Leg Ischaemia Prevention Study (CLIPS) Group. Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261: 276-284.
• 17 Belch J, MacCuish A, Campbell I. et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008; 337: a1840.
• 18 Fowkes FG, Price JF, Stewart MC. et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. J Am Med Assoc 2010; 303: 841-848.
• 19 Basili S, Raparelli V, Vestri A. et al. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost 2010; 103: 766-773.
• 20 Davì G, Gresele P, Violi F. et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
• 21 Gresele P, Catalano M, Giammarresi C. et al. Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. Thromb Haemost 1997; 78: 1434-1437.
• 22 Mohan IV, Mikhailidis DP, Stansby GP. Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg 2007; 41: 322-329.
• 23 Tsakiris DA, Tschöpl M, Wolf F. et al. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 2000; 11: 165-173.
• 24 Holme PA, Orvim U, Hamers MJ. et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17: 646-653.
• 25 Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res 1999; 8: 9-16.
• 26 Wang Z, Ciabattoni G, Creminon C. et al. Immunological characterization of uri-nary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
• 27 Ciabattoni G, Maclouf J, Catella F. et al. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-297.
• 28 Varo N, Nuzzo R, Natal C. et al. Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci 2006; 111: 341-347.
• 29 Santilli F, Basili S, Ferroni P. et al. CD40/CD40L system and vascular disease. Intern Emerg Med 2007; 2: 256-268.
• 30 Santilli F, Davì G, Consoli A. et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47: 391-397.
• 31 Fujiwara N, Osanai T, Kamada T. et al. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101: 856-861.
• 32 Di Stefano R, Barsotti MC, Melillo E. et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008; 100: 871-877.
• 33 Davì G, Catalano I, Averna M. et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774.
• 34 Patrono C, Ciabattoni G, Davì G. Thromboxane biosynthesis in cardiovascular diseases. Stroke 1990; 21: IV130-133.
• 35 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
• 36 Santilli F, Romano M, Recchiuti A. et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood 2008; 112: 1085-1090.
• 37 Eikelboom JW, Hankey GJ, Thom J. et al. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators.. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
• 38 Anfossi G, Russo I, Massucco P. et al. Impaired synthesis and action of antiaggre-gating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004; 34: 482-489.
• 39 Reilly MP, Mohler ER. 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35: 48-56.
• 40 Burdess A, Nimmo AF, Garden OJ. et al. Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Ischemia. Ann Surg 2010; 252: 37-42.
• 41 Blardi P, de Lalla A, Pieragalli D. et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Prostaglandins Other Lipid Mediat 2006; 80: 175-182.
• 42 Higashi Y, Nishioka K, Umemura T. et al. Oxidative stress, endothelial function and angiogenesis induced by cell therapy and gene therapy. Curr Pharm Biotechnol 2006; 7: 109-116.
• 43 Patrono C, Falco A, Davì G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 2005; 5: 198-203.
• 44 Davì G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149-163.
• 45 Hsieh CJ, Wang PW. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circ J 2009; 73: 948-954.
• 46 Ferroni P, Santilli F, Guadagni F. et al. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem 2007; 14: 2170-2180.
• 47 Davì G, Ferroni P. CD40-CD40L interactions in platelet activation. Thromb Haemost 2005; 93: 1011-1012.
• 48 Blann AD, Tan KT, Tayebjee MH. et al. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93: 578-583.
• 49 Di Renzo M, Pieragalli D, Meini S. et al. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 405-410.
• 50 Chung A, Wildhirt SM, Wang S. et al. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study. J Thorac Cardiovasc Surg 2005; 129: 782-790.
• 51 Jörres A, Dinter H, Topley N. et al. Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 1997; 9: 119-125.
• 52 Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356: 830-840.
• 53 Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992; 43: 889-924.
• 54 Cipollone F, Mezzetti A, Porreca E. et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
• 55 Santilli F, Bucciarelli L, Noto D. et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007; 43: 1255-1262.
• 56 Schellong S, Altmann E, von Bilderling P. et al. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 503-509.